Since the late nineties, it is well known that PSMA antibodies not only bind to tumor cells within prostate carcinoma samples, but also to the neovasculature of a variety of other solid tumors, e.g., breast and colon carcinoma, melanoma, and glioblastoma (Haffner et al, 2012; Ren et al, 2014; Wernicke et al, 2014). The gene discussed is FOLH1; the disease is prostate carcinoma.